Statistical Significance Met on Primary Endpoints of 1 Year Survival Rate and Median Overall SurvivalDoubling of 1 Year ...

PanCAN Chief Scientific & Medical Officer Dr. Anna Berkenblit looks back on the progress made toward better understanding and ...

The trial of the company’s metastatic pancreatic cancer treatment, elraglusib, similarly saw the one-year survival rate reach ...

The FDA advised that the on-going VIRAGE Phase 2b study should not be expanded into a Phase 3 study; rather, the optimal path forward for the VCN-01 PDAC program is to conduct a stand-alone Phase 3 ...

“The FDA approval of Bizengri marks an important milestone for patients with pancreatic adenocarcinoma or NSCLC that is advanced unresectable or metastatic and harbors the NRG1 gene fusio ...

Shares of Actuate Therapeutics on Tuesday climbed after the company said that it received positive data from its phase 2 trial of elraglusib in combination with gemcitabine/nab-paclitaxel to treat ...

(a) Axial T2-weighted fat sat image and (b) corresponding axial T1-weighted fat sat contrast-enhanced image of a patient with pancreatic adenocarcinoma are shown. Note the presence of small ...

Key eligibility criteria were patients age 18 years or older and had undergone complete macroscopic resection for ductal adenocarcinoma of the pancreas. Country of participation and resection margin ...